All
FDA Grants Capivasertib Plus Faslodex Priority Review for Breast Cancer
June 13th 2023The application for capivasertib plus Faslodex in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer has also been granted priority review, meaning that the FDA has six months to make a decision.